Agenus reports phase II data demonstrating immune reprogramming and durable survival with botensilimab, balstilimab and agent-797 in PD-1 refractory gastroesophageal cancer

Published: 2026-04-17 16:49:42 ET AGEN

Published on 04/17/2026 at 04:49 pm EDT